Fundamental concepts and novel aspects of polycystic ovarian syndrome: expert consensus resolutions

A Aversa, S La Vignera, R Rago, A Gambineri… - Frontiers in …, 2020 - frontiersin.org
Polycystic ovary syndrome (PCOS) is a very common endocrine and metabolic disorder with
the involvement of both genetic and environmental factors. Although much has been …

Poly cystic ovarian syndrome: an updated overview

S El Hayek, L Bitar, LH Hamdar, FG Mirza… - Frontiers in …, 2016 - frontiersin.org
Poly Cystic Ovarian Syndrome (PCOS) is one of the most common metabolic and
reproductive disorders among women of reproductive age. Women suffering from PCOS …

[HTML][HTML] Polycystic ovarian syndrome-current pharmacotherapy and clinical implications

R Rashid, SA Mir, O Kareem, T Ali, R Ara… - Taiwanese Journal of …, 2022 - Elsevier
Polycystic ovary syndrome (PCOS), the most common endocrinopathy in women is
characterized by polycystic ovaries, chronic anovulation and hyperandrogenism. The …

Inositols in PCOS

Z Kamenov, A Gateva - Molecules, 2020 - mdpi.com
(1) Background: Myoinositol (MI) and D-chiro-inositol (DCI) are involved in a number of
biochemical pathways within oocytes having a role in oocyte maturation, fertilization …

Antioxidants for female subfertility

MG Showell, R Mackenzie-Proctor… - … of systematic reviews, 2020 - cochranelibrary.com
Background A couple may be considered to have fertility problems if they have been trying
to conceive for over a year with no success. This may affect up to a quarter of all couples …

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

LC Morley, T Tang, E Yasmin… - Cochrane Database …, 2017 - cochranelibrary.com
Background Polycystic ovary syndrome (PCOS) is characterised by infrequent or absent
ovulation, and high levels of androgens and insulin (hyperinsulinaemia). Hyperinsulinaemia …

Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials

V Unfer, F Facchinetti, B Orrù, B Giordani… - Endocrine …, 2017 - ec.bioscientifica.com
Myo-inositol (MI) supplementation in women with polycystic ovary syndrome (PCOS) has
been evaluated over the last years. Many hormonal and reproductive impairments …

Pharmacodynamics and pharmacokinetics of inositol (s) in health and disease

M Bizzarri, A Fuso, S Dinicola, A Cucina… - Expert opinion on …, 2016 - Taylor & Francis
Introduction: Inositol and its derivatives comprise a huge field of biology. Myo-inositol is not
only a prominent component of membrane-incorporated phosphatidylinositol, but …

Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology-based approach

AS Laganà, S Garzon, J Casarin, M Franchi… - Trends in endocrinology …, 2018 - cell.com
Myo-inositol (MI) and D-chiro-inositol (DCI) are insulin second messengers, and MI is
involved in follicular gonadotropin pathways which orchestrate ovulation. The tissue-specific …

Effects of inositol (s) in women with PCOS: a systematic review of randomized controlled trials

V Unfer, JE Nestler, ZA Kamenov… - International journal …, 2016 - Wiley Online Library
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with complex etiology
and pathophysiology, which remains poorly understood. It affects about 5–10% of women of …